KAS
AKBA icon

Kestra Advisory Services’s Akebia Therapeutics AKBA Stock Holding History

Kestra Advisory Services’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.9K Sell
25,074
-6,850
-21% -$9.41K ﹤0.01% 3073
2025
Q4 		$51.4K Buy
31,924
+2,150
+7% +$4.5K ﹤0.01% 3917
2025
Q3 		$81.3K Buy
29,774
+13,300
+81% +$44.2K ﹤0.01% 2829
2025
Q2 		$60K Buy
+16,474
New +$45.3K ﹤0.01% 2762

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Kestra Advisory Services's AKBA Position: Q1 2026 in Review

Kestra Advisory Services reduced its Akebia Therapeutics (AKBA) stake by 21% in Q1 2026, selling an estimated $9.41K and leaving 25,074 shares worth $34.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3073.

Kestra Advisory Services first reported a position in AKBA in Q2 2025 and has held it in 4 quarters since. The position peaked at $81.3K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Kestra Advisory Services held 25,074 shares of Akebia Therapeutics worth $34.9K as of Q1 2026.
  • Kestra Advisory Services sold 6,850 Akebia Therapeutics shares in Q1 2026, an estimated $9.41K.
  • Akebia Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q1 2026, its #3073 holding.
  • Kestra Advisory Services first reported a position in Akebia Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Kestra Advisory Services's Akebia Therapeutics position peaked at $81.3K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.